Skip to main navigation

Top Menu

About Us
Our Science
Pipeline
Partnering
Investors & Media
Careers
Contact

Investors & Media

Presentations

Entasis Corporate Presentation - April

Press Releases

Year

Entasis Therapeutics Initiates Clinical Studies of the Oral Extended-Spectrum Beta-Lactamase Inhibitor ETX0282

May 14, 2018

Entasis Therapeutics Appoints David C. Hastings to Board of Directors

May 01, 2018

Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514

Apr 25, 2018

Entasis Therapeutics Receives Second CARB-X Award, Providing up to $10.1 Million for Development of Non-Beta-lactam PBP Inhibitor Program

Oct 12, 2017

Entasis Therapeutics Highlights Positive Phase 1 Data for ETX2514 at IDWeek 2017, Announces Plans to Advance Combination with sulbactam (ETX2514SUL) into Phase 2 Trials

Oct 09, 2017

Entasis Therapeutics to Present Phase 1 Data on ETX2514 at IDWeek 2017

Sep 28, 2017

Entasis Announces $31.9 Million Extension of Series B Financing to Advance Anti-infective Therapeutic Portfolio

Sep 05, 2017

Entasis Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) to Develop a New Treatment for Drug-Resistant Gonorrhea

Jul 06, 2017

Entasis Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations against Drug Resistant Gram-negative Bacteria Including Acinetobacter and Pseudomonas

Jun 30, 2017

Entasis Therapeutics Presents Data on Third Drug Candidate, ETX0282, an Orally Available, Extended-Spectrum Βeta-lactamase Inhibitor, at ASM Microbe 2017

Jun 07, 2017

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Next page
Last page

Displaying 21 - 30 of 47

Toolkit

Print page
RSS Feeds
Email Alerts
Search

Investor Relations

Corporate Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
SEC Filings
Corporate Governance
Investor Resources

"Antibiotic resistance is a worldwide problem that is constantly growing. New forms of resistance can spread quickly and across continents. At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections."

— Ruben Tommasi, Chief Scientific Officer

©2019 Entasis Therapeutics Inc.

Terms of Use | Privacy Policy